NCT05008913View on ClinicalTrials.gov

Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib

PHASE1TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

November 16, 2021

Study Completion Date

November 16, 2021

Conditions

Advanced Solid Tumors

Interventions

DRUG

[14C]Adavosertib

Patients will receive a single administration of \[14C\]Adavosertib as an oral solution on Day 1.

Trial Locations (1)

M20 4BX

Research Site, Manchester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY